US · Healthcare · Biotechnology
EPS came in at -0.72 against a street estimate of -0.72 — a beat of 0.0%.
Analysts rate Replimune Group Inc a buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $19.50.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 11.72% |
| BlackRock Inc | 9.51% |
| RTW INVESTMENTS, LLC | 7.87% |
| Ridgeback Capital Investments L.p. | 7.76% |
| State Street Corp | 4.71% |
| Suvretta Capital Management, LLC | 4.66% |
| Boxer Capital Management, LLC | 4.23% |
| Vanguard Capital Management, LLC | 3.07% |
| Document | Date |
|---|---|
| Charter / bylaws change · Q2 FY2027 REPLIMUNE GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held September 15, 2026 • Authorized common shares increased | 2026-09-16 |
| Quarterly report · Q1 FY2027 REPLIMUNE GROUP, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Equivalents: $185.4 million as of June 30, | 2026-08-14 |
| Results announced · Q2 FY2027 REPLIMUNE GROUP, INC. – FISCAL Q1 2027 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • FDA Approval & Launch: TUDRIQEV (vusolimogene oderparepvec-wtpg) | 2026-08-14 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. - FORM 8-K SUMMARY August 9, 2026 Stock Offering --- HEADLINE NUMBERS • Company raising approximately $140.5 million in net p | 2026-08-10 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Replimune Group, Inc. (ticker: REPL, Nasdaq) • Filing date: August 6, 2026 • He | 2026-08-07 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Advisory Committee Vote: FDA's Cellular, Tissue, and Gene Therapies Advisory Committee v | 2026-07-31 |
| Proxy statement · Q2 FY2027 REPLIMUNE GROUP, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Ratify PricewaterhouseCoopers LLP as independent audit | 2026-07-29 |
| Annual report FY2026 REPLIMUNE GROUP, INC. - FORM 10-K SUMMARY Fiscal Year Ended March 31, 2026 --- HEADLINE NUMBERS • Market capitalization: $234.5 million (aggregate | 2026-06-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Replimune Group Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.